Physician profile
Ivan Wong
NPI 1356608426
$7,579.44
in general payments reported to CMS, 2019-2025
27 companies · $2,611 in 2025
The $2,611 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2022: $930 · 2023: $2,039 · 2024: $1,859 · 2025: $2,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,226 · Consulting Fee: $1,860 · Education: $365 · Travel and Lodging: $58.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,225.98 |
| Consulting Fee | $1,860.00 |
| Education | $365.30 |
| Travel and Lodging | $58.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,253.45 | 2022-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $513.16 | 2024-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $424.19 | 2024-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Insmed, INC. | $392.66 | 2019-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $358.25 | 2023-2025 | Opsumit, Uptravi |
| Genzyme Corporation | $316.57 | 2024-2025 | |
| Vifor Pharma, INC. | $266.49 | 2024-2025 | Zemaira, Veltassa |
| Smith+Nephew, INC. | $229.76 | 2025 | Smith & Nephew Insufflator 500, Aetos Shoulder System |
| Regeneron Healthcare Solutions, INC. | $225.32 | 2024-2025 | Dupixent |
| Viatris Specialty LLC | $195.64 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $179.30 | 2024-2025 | |
| Olympus America INC. | $144.45 | 2024 | Spin Vision Video Processor |
| Baxter Healthcare | $139.59 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Gilead Sciences, INC. | $125.00 | 2024 | Livdelzi |
| Boston Scientific Corporation | $116.38 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $104.58 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $97.14 | 2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $91.52 | 2025 | Acthar |
| Philips North America LLC | $86.23 | 2025 | Vest Therapy Und |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Electromed, INC. | $54.96 | 2024-2025 | Smartvest |
| Grifols USA, LLC | $42.67 | 2024-2025 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $35.41 | 2024 | Bridion, Winrevair |
| Genentech USA, INC. | $31.96 | 2024 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $31.94 | 2024 | Glassia |
| Amgen INC. | $22.30 | 2025 | Tezspire |
| United Therapeutics Corporation | $21.53 | 2025 | Tyvaso |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.